- Home
- SGRY vs BHVN Comparison
SGRY vs BHVN Comparison
Compare SGRY & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGRY
- BHVN
- Stock Information
- Founded
- SGRY 2004
- BHVN 2013
- Country
- SGRY United States
- BHVN United States
- Employees
- SGRY N/A
- BHVN N/A
- Industry
- SGRY Hospital/Nursing Management
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- SGRY Health Care
- BHVN Health Care
- Exchange
- SGRY Nasdaq
- BHVN Nasdaq
- Market Cap
- SGRY 3.8B
- BHVN 3.7B
- IPO Year
- SGRY 2015
- BHVN 2017
- Fundamental
- Price
- SGRY $30.51
- BHVN $37.13
- Analyst Decision
- SGRY Buy
- BHVN Strong Buy
- Analyst Count
- SGRY 7
- BHVN 10
- Target Price
- SGRY $39.86
- BHVN $54.44
- AVG Volume (30 Days)
- SGRY 1.0M
- BHVN 665.4K
- Earning Date
- SGRY 11-05-2024
- BHVN 08-08-2024
- Dividend Yield
- SGRY N/A
- BHVN N/A
- EPS Growth
- SGRY N/A
- BHVN N/A
- EPS
- SGRY N/A
- BHVN N/A
- Revenue
- SGRY $2,889,000,000.00
- BHVN N/A
- Revenue This Year
- SGRY $14.72
- BHVN N/A
- Revenue Next Year
- SGRY $9.47
- BHVN N/A
- P/E Ratio
- SGRY N/A
- BHVN N/A
- Revenue Growth
- SGRY 8.55
- BHVN N/A
- 52 Week Low
- SGRY $22.05
- BHVN $16.45
- 52 Week High
- SGRY $36.92
- BHVN $62.21
- Technical
- Relative Strength Index (RSI)
- SGRY 51.73
- BHVN 43.67
- Support Level
- SGRY $29.24
- BHVN $35.29
- Resistance Level
- SGRY $30.55
- BHVN $37.86
- Average True Range (ATR)
- SGRY 1.00
- BHVN 1.43
- MACD
- SGRY -0.22
- BHVN -0.48
- Stochastic Oscillator
- SGRY 26.22
- BHVN 16.65
About SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It operates in two segments: Surgical Facility Services and Ancillary Services out of which the Surgical Facility Services segment accounts for the majority of revenue.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.